» Articles » PMID: 17687565

Prediction of Response and Prognostic Factors for Ewing Family of Tumors in a Low Incidence Population

Abstract

Purpose: There is some unknown reason Ewing family of tumors (EFTs) is much less common on Asia and Africa than in the Western Caucasian population. This study analyzed the prediction of response and prognostic factors for Ewing family of tumors (EFTs) in an Asian population with a low incidence.

Methods: We retrospectively reviewed 94 patients with EFTs between 1978 and 2006. Fifteen patients received local therapy only. Statistical analyses were performed for 79 patients, including those who received systemic chemotherapy, to identify factors related to chemotherapy responsiveness, event-free survival, and overall survival.

Results: Of the 79 patients whose records were analyzed, the 5-year event-free rate and overall survival (OS) rate were 41 and 54%, respectively. The response rate to first-line chemotherapy was 61% in 70 patients with assessable lesions. A significant predictor of response was existence of a non-pelvic primary tumor (P = 0.04). Significant prognostic factors for OS were age, performance status, and metastases at the time of diagnosis (P < 0.01, respectively). Fifty-four patients had disease progression or recurrence after first-line treatment. The time to progression was 3.4 months after salvage treatment. Progression during first-line treatment was significantly associated with time to progression after salvage treatment (P = 0.01). All patients treated without chemotherapy in first-line treatment were recurred with poor prognosis.

Conclusion: A non-pelvic primary tumor was a favorable predictor of responsiveness to chemotherapy. Chemo-resistant patients might less benefit from second line chemotherapy. Chemotherapy in first-line treatment should not be omitted, even if primary tumor was extirpated completely.

Citing Articles

Role of radiation therapy in the multidisciplinary management of Ewing's Sarcoma of bone in pediatric patients: An effective treatment for local control.

Lopez J, Cabrera P, Ordonez R, Marquez C, Ramirez G, Praena-Fernandez J Rep Pract Oncol Radiother. 2013; 16(3):103-9.

PMID: 24376965 PMC: 3863312. DOI: 10.1016/j.rpor.2011.01.006.


Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.

Roundhill E, Burchill S Br J Cancer. 2013; 109(1):195-206.

PMID: 23799853 PMC: 3708562. DOI: 10.1038/bjc.2013.168.


The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

van Maldegem A, Hogendoorn P, Hassan A Clin Sarcoma Res. 2012; 2(1):7.

PMID: 22587879 PMC: 3351700. DOI: 10.1186/2045-3329-2-7.


Prognostic factors for overall survival in paediatric patients with Ewing sarcoma of bone treated according to multidisciplinary protocol.

Lopez Guerra J, Marquez-Vega C, Ramirez-Villar G, Cabrera P, Ordonez R, Praena-Fernandez J Clin Transl Oncol. 2012; 14(4):294-301.

PMID: 22484637 DOI: 10.1007/s12094-012-0798-y.

References
1.
Guo W, Xu W, Huvos A, Healey J, Feng C . Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl). 2001; 112(12):1101-4. View

2.
Nesbit Jr M, Gehan E, BURGERT Jr E, Vietti T, Cangir A, Tefft M . Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990; 8(10):1664-74. DOI: 10.1200/JCO.1990.8.10.1664. View

3.
Rodriguez-Galindo C, Spunt S, Pappo A . Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003; 40(5):276-87. DOI: 10.1002/mpo.10240. View

4.
Villarroel M, Tordecilla J, Salgado C, Luo X, Messen S, Rayo Y . Multimodal therapy for children and adolescents with Ewing sarcoma: results of the First National Chilean Trial (1986-1991). Med Pediatr Oncol. 1997; 29(3):190-6. DOI: 10.1002/(sici)1096-911x(199709)29:3<190::aid-mpo5>3.0.co;2-8. View

5.
Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P . Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18(1):4-11. DOI: 10.1200/JCO.2000.18.1.4. View